Literature DB >> 21223250

Impact of reduced chemotherapy treatment for good risk childhood acute lymphoblastic leukaemia on infectious morbidity*.

Cornelis M van Tilburg1, Elisabeth A M Sanders, Elisabeth E Nibbelke, Rob Pieters, Tom Revesz, Paul Westers, Tom F W Wolfs, Marc B Bierings.   

Abstract

Reducing infectious morbidity is an important goal to improve childhood acute lymphoblastic leukaemia (ALL) survival. To explore the impact of chemotherapy reduction on infectious morbidity, we compared outpatient and inpatient infectious morbidity of reduced versus intensive (conventional) chemotherapy. One hundred and seventy-one children newly diagnosed with ALL between 2004 and 2007 and treated according to the Dutch Childhood Oncology Group ALL 10 protocol were prospectively followed during the 2-year treatment course. Stratified by minimal residual disease, 54 patients received reduced (standard risk; SR) and 117 patients received intensive (medium risk; MR) intensification/maintenance treatment. SR outpatients had a median of 1 febrile episode versus 4 in MR outpatients (P=0·002). SR patients had fewer hospitalizations for fever. They were admitted a median of 0 times, with a median of 0days of hospitalization, median 0days of fever, median 0 times chemotherapy interruption and median 0 times intravenous antibiotics. MR patients were admitted for fever median 2 times (P<0·001) with 10days of hospitalization (P<0·001), 2days of fever (P<0·001), one chemotherapy interruption (P<0·001) and two intravenous antibiotics administration (P<0·001). These data indicate that reduced intensification/maintenance compared to conventional intensive intensification/maintenance chemotherapy for good risk childhood ALL resulted in major decrease of infectious morbidity.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21223250     DOI: 10.1111/j.1365-2141.2010.08463.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Prevalence and Safety of Intravenous Immunoglobulin Administration During Maintenance Chemotherapy in Children with Acute Lymphoblastic Leukemia in First Complete Remission: A Health Maintenance Organization Perspective.

Authors:  Patrick Van Winkle; Raoul Burchette; Raymond Kim; Rukmani Raghunathan; Naveen Qureshi
Journal:  Perm J       Date:  2018

2.  Immune reconstitution in children following chemotherapy for acute leukemia.

Authors:  Anthony P Williams; Jessica Bate; Rachael Brooks; Julia Chisholm; Stuart C Clarke; Elizabeth Dixon; Saul N Faust; Angeliki Galanopoulou; Paul T Heath; Thomas Maishman; Susan Mapstone; Soonie R Patel; Ajay Vora; Sam A Wilding; Juliet C Gray
Journal:  EJHaem       Date:  2020-06-10

3.  Illness cognitions and family adjustment: psychometric properties of the Illness Cognition Questionnaire for parents of a child with cancer.

Authors:  Simone M Sint Nicolaas; Sasja A Schepers; Esther M M van den Bergh; Andrea W M Evers; Peter M Hoogerbrugge; Martha A Grootenhuis; Christianne M Verhaak
Journal:  Support Care Cancer       Date:  2015-06-25       Impact factor: 3.603

4.  Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.

Authors:  Xin-Yu Li; Jia-Qiang Li; Xue-Qun Luo; Xue-Dong Wu; Xin Sun; Hong-Gui Xu; Chang-Gang Li; Ri-Yang Liu; Xiao-Fei Sun; Hui-Qin Chen; Yu-Deng Lin; Chi-Kong Li; Jian-Pei Fang
Journal:  BMC Cancer       Date:  2021-01-13       Impact factor: 4.430

5.  Predicting trajectories of behavioral adjustment in children diagnosed with acute lymphoblastic leukemia.

Authors:  Simone M Sint Nicolaas; Peter M Hoogerbrugge; Esther M M van den Bergh; José A E Custers; Sofia Gameiro; Reinoud J B J Gemke; Chris M Verhaak
Journal:  Support Care Cancer       Date:  2016-06-14       Impact factor: 3.603

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.